Law Firm Brower Piven Announces Investigation of Investor Securities Fraud Against Celsion Corporati

Updated

Law Firm Brower Piven Announces Investigation of Investor Securities Fraud Against Celsion Corporation

STEVENSON, Md.--(BUSINESS WIRE)-- The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against Celsion Corporation ("Celsion") (NAS: CLSN) regarding whether Celsion may have issued materially false or misleading information to investors before announcing on January 31, 2013 that its ThermoDox liver cancer treatment failed in a study and did not meet its primary endpoint.

If you purchased or acquired Celsion securities between January 1, 2012 and January 30, 2013 and have suffered a loss on your investment, or if you believe you have information relating to the subject matter of our investigation, you may email or call Brower Piven, who will, without obligation or cost to you, communicate with you regarding the matter and attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling 410/415-6616, or by writing to Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.




Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com

KEYWORDS: United States North America District of Columbia Maryland

INDUSTRY KEYWORDS:

The article Law Firm Brower Piven Announces Investigation of Investor Securities Fraud Against Celsion Corporation originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement